RGT — Argent BioPharma Share Price
Last trade - 00:00- £3.47m
- £3.30m
- AU$0.89m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.87 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -2015.13% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 2.08 | 3 | 4.73 | 3.39 | 0.89 | 19.1 | 24.2 | 6.31% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Argent BioPharma Ltd, formerly MGC Pharmaceuticals Ltd, is an Australia-based drug discovery company. The Company is focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologies. Its approach combines in-house research with technology, all discovering and producing treatments for unmet medical conditions. Its investigational medicinal (IMPs) products include CannEpil, CimetrA and CogniCann. CimetrA is a phyto medicine based on natural ingredients from Curcumin and Boswellia serrata, delivered in the nanoparticle delivery system, which is being developed for acute lung injury and acute respiratory distress syndrome (ARDS). CannEpil is a phyto medicine based on phytocannabinoid is being developed for the treatment of refractory epilepsy and cerebral palsy. CogniCann is a phyto medicine based on phytocannabinoids is in investigation stage as a treatment for the symptoms associated with dementia and Alzheimer.
Directors
- Brett Mitchell CHM
- Roby Zomer CEO
- Amir Polak CTO
- Nativ Segev EDR
- Nicole Godresse OTH
- Sabina Suljakovic OTH
- Rachel Kerr SEC
- David Lim SEC (50)
- Stephen Parker NED (62)
- Evan Hayes NID
- Ross Grant Thomas Walker NID
- Last Annual
- June 30th, 2024
- Last Interim
- June 30th, 2024
- Incorporated
- October 21st, 2005
- Public Since
- December 21st, 2006
- No. of Shareholders
- 9,140
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 45,280,202
- Address
- Suite 1, 295 Rokeby Road, SUBIACO, 6008
- Web
- https://argentbiopharma.com/
- Phone
- +61 865552950
- Auditors
- Hall Chadwick
Latest News for RGT
Upcoming Events for RGT
Half Year 2025 MGC Pharmaceuticals Ltd Earnings Release
Similar to RGT
Alliance Pharma
London Stock Exchange
Animalcare
London Stock Exchange
AstraZeneca
London Stock Exchange
Beximco Pharmaceuticals
London Stock Exchange
BSF Enterprise
London Stock Exchange
FAQ
As of Today at 18:20 UTC, shares in Argent BioPharma are trading at 6.50p. This share price information is delayed by 15 minutes.
Shares in Argent BioPharma last closed at 6.50p and the price had moved by -75.93% over the past 365 days. In terms of relative price strength the Argent BioPharma share price has underperformed the FTSE All Share Index by -77.12% over the past year.
The overall consensus recommendation for Argent BioPharma is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreArgent BioPharma does not currently pay a dividend.
Argent BioPharma does not currently pay a dividend.
Argent BioPharma does not currently pay a dividend.
To buy shares in Argent BioPharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 6.50p, shares in Argent BioPharma had a market capitalisation of £3.47m.
Here are the trading details for Argent BioPharma:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: RGT
Based on an overall assessment of its quality, value and momentum Argent BioPharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Argent BioPharma is 1,911.18p. That is 29302.72% above the last closing price of 6.50p.
Analysts covering Argent BioPharma currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.04 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Argent BioPharma. Over the past six months, its share price has underperformed the FTSE All Share Index by -63.9%.
As of the last closing price of 6.50p, shares in Argent BioPharma were trading -64.12% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Argent BioPharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 6.50p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Argent BioPharma's management team is headed by:
- Brett Mitchell - CHM
- Roby Zomer - CEO
- Amir Polak - CTO
- Nativ Segev - EDR
- Nicole Godresse - OTH
- Sabina Suljakovic - OTH
- Rachel Kerr - SEC
- David Lim - SEC
- Stephen Parker - NED
- Evan Hayes - NID
- Ross Grant Thomas Walker - NID